Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding

Acute Variceal Bleeding (AVB) in patients with liver cirrhosis is a common clinical critical disease.There is little evidence for the effect of PPI use in patients with AVB in liver cirrhosis, and there is no study on the efficacy of PPI combined with standard therapy in patients with AVB.

Inclusion Criteria:Liver cirrhosis.The etiology of portal hypertension is cirrhosis.Patients presenting with acute esophageal variceal bleeding proven by emergency endoscopy within 24 hours.Be willing to participate in this clinical study, comply with the study requirements and sign the informed consentExclusion Criteria:non-cirrhotic portal hypertensionthe time from admission to endoscopy was more than 24 hourspatients with peptic ulcer or gastroesophageal reflux disease requiring PPI therapyPPI use for more than 2 weeks before admissionreceived endoscopic or interventional therapy within the previous 4 weeksPPI allergyChronic renal insufficiency (CKD stage 3-5)Severe cardiopulmonary dysfunction (such as heart failure grade 3-4, respiratory failure, etc.)Hepatocellular carcinoma (Barcelona Clinic Liver Cancer (BCLC) stage C and D)other advanced malignancies (life expectancy less than 6 months)Pregnancy